RPCONE
ZVRA icon

Retirement Planning Company of New England’s Zevra Therapeutics ZVRA Stock Holding History

Retirement Planning Company of New England’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.1M Sell
634,410
-16,738
-3% -$186K 3.27% 3
2026
Q1 		$6.07M Sell
651,148
-11,828
-2% -$107K 2.47% 4
2025
Q4 		$5.94M Buy
662,976
+62,206
+10% +$588K 2.38% 4
2025
Q3 		$5.71M Buy
600,770
+47,473
+9% +$476K 2.3% 4
2025
Q2 		$4.87M Buy
553,297
+3,117
+0.6% +$25.3K 2.17% 5
2025
Q1 		$4.12M Buy
550,180
+35,348
+7% +$281K 2.05% 5
2024
Q4 		$4.29M Buy
514,832
+15,327
+3% +$131K 2.08% 6
2024
Q3 		$3.47M Buy
499,505
+41,205
+9% +$280K 1.73% 9
2024
Q2 		$2.25M Buy
458,300
+28,107
+7% +$133K 1.22% 18
2024
Q1 		$2.5M Buy
430,193
+42,766
+11% +$263K 1.37% 14
2023
Q4 		$2.54M Buy
387,427
+40,025
+12% +$187K 1.14% 20
2023
Q3 		$1.67M Sell
347,402
-7,371
-2% -$36.8K 0.93% 28
2023
Q2 		$1.81M Buy
354,773
+27,190
+8% +$147K 1.04% 20
2023
Q1 		$1.8M Buy
327,583
+30,199
+10% +$160K 1.09% 18
2022
Q4 		$1.36M Sell
297,384
-5,436
-2% -$27.6K 0.89% 27
2022
Q3 		$1.89M Buy
302,820
+14,900
+5% +$84.4K 1.37% 12
2022
Q2 		$1.28M Buy
287,920
+44,029
+18% +$201K 0.88% 28
2022
Q1 		$1.23M Buy
243,891
+32,823
+16% +$209K 0.69% 36
2021
Q4 		$1.84M Buy
+211,068
New +$1.88M 0.89% 18

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Retirement Planning Company of New England's ZVRA Position: Q2 2026 in Review

Retirement Planning Company of New England reduced its Zevra Therapeutics (ZVRA) stake by 2.6% in Q2 2026, selling an estimated $186K and leaving 634,410 shares worth $9.1M. The position accounts for 3.27% of the portfolio, ranked #3.

Retirement Planning Company of New England first reported a position in ZVRA in Q4 2021 and has held it in 19 quarters since. 82 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Retirement Planning Company of New England held 634,410 shares of Zevra Therapeutics worth $9.1M as of Q2 2026.
  • Retirement Planning Company of New England sold 16,738 Zevra Therapeutics shares in Q2 2026, an estimated $186K.
  • Zevra Therapeutics made up 3.27% of Retirement Planning Company of New England's portfolio in Q2 2026, its #3 holding.
  • Retirement Planning Company of New England first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 82 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Retirement Planning Company of New England's 13F filing for Q2 2026, filed 30 Jul 2026.